GLAXF News and Press, GlaxoSmithKline Plc From 11/25/20

GlaxoSmithKline remains a high-yield pick in pharma, partially a consequence of several years of little growth and portfolio attrition to generics. Recent waves of drugs falling off-patent leave a substantial portfolio with a long while till patents expire. With three promising ap...

Silverback Therapeutics has filed to raise $100 million in an IPO, although the final figure may differ. The firm is developing treatments for various cancers and Hepatitis B. SBTX may have had positive response rates in early trials for its lead candidate. For further detai...

Fisher’s 13F portfolio value increased from $102.5B to $117.8B in Q3 2020. They increased NextEra Energy, UnitedHealth, 3M Company, and Thermo Fisher Scientific while decreasing Starbucks, Total SA, and Royal Dutch Shell during the quarter. Fisher has a number of small posi...

GSK and ABBV are both attractively valued and high-yield picks available in the pharma space, discounted for their respective generics-eroded segments. We think that neither is a bad option in the long term, but would opt for GSK due to its lesser focus on oncology, a market that is b...

Clovis Oncology is a higher-risk holding that has significant risk baked into the future outlook, and larger players have better product labels in our view. The company's cash position is tight, and we question the runaway guided by management, plus see evidence of poor liquidity thro...

Like every week on my TEV blog, I want to show you some stocks that will go ex-dividend in the next few days. I'll also review a few companies currently in the focus of investors or that have an attractive fundamental valuation. Additionally, I'll give you some insights into my re...

The FDA lifted all holds on all CymaBay liver disease studies back in July, since, shares have begun clawing back, +319% upside YTD. The company has presented positive top-line data from the ENHANCE study for Seladelpar, which shows high conversion potential in a complex chronic disea...

Vir Biotechnology has a deep pipeline across many disease segments, reducing concentration risk in the portfolio and expanding commercial reach. The company has key collaborations with large players, providing long-tailed asset returns whilst partners do the heavy lifting in commercia...

Kahn Brothers’ 13F portfolio value decreased from $592M to $528M this quarter. Patterson-UTI was increased while reducing Merck, Seaboard, Sterling Bancorp, and Hologic. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 1...

Projecting Innoviva's earnings is pretty easy. For professional investors, it's even easier. Yet the stock fluctuates like crazy, and often, the highest volatility comes when earnings have just been revealed. The sometimes evident disconnect between market action and certain funda...